This is a Phase 2 study investigating safety and tolerability of Inhaled Treprostinil in participants with Pulmonary Hypertension associated with Interstitial Lung Disease.
Insmed TPIP Study
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Interstitial lung diseases, Pulmonary hypertension
All genders
18-75
Recruiting now
Overview
Principal Investigator: Nicholas Hill, MD
Contact Us
Bipin Malla
Study details
Inclusion Criteria
- Diagnosis of Pulmonary Hypertension associated with Interstitial Lung Disease (including IIP, IPF, CTD, sarcoidosis)
- Qualifying results in Pulmonary Function test at screening
- Can walk at least 100 meters in 6 minute walk test
Exclusion Criteria
- Primary diagnosis of chronic obstructive pulmonary disease (COPD)
- Received or currently treatment with any pulmonary hypertension medication in past 30 days
- History of Heart Disease
Study Requirements
Total of Eight clinic visits in a span of 20 weeks with Spirometry tests on all visits. All participants will undergo High resolution CT scan at the beginning and end of the study. Blood draws during six out of eight study visits.